

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) with respect to a report recently issued by Flaming Research (“**Flaming**”) (the “**Report**”) which contains allegations against the Company, and is published by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement of the Company dated 28 September 2018 in relation to the Report and the Company’s refutation and/or clarification of the allegations made in the Report (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

THE REPORT

On 27 September 2018, the Company noted that the Report against the Company was published by Flaming which contains untrue and groundless allegations against the Group. Due to the severe drop in the Company’s share price subsequent to the publication of the Report, shares of the Company were halted for trading on the same day. As set out in the Announcement, the Company took the view that the allegations and information contained in the Report are misleading, biased, selective, inaccurate and incomplete as well as groundless allegations and irresponsible speculations. The allegations in the Report have seriously damaged the Company’s corporate image, credit and reputation, and have caused significant fluctuation in the share price of the Company.

In order to protect the interest of shareholders (the “**Shareholders**”) and potential investors of the Company, the Company is taking all necessary legal actions and has undertaken the following actions as of the date of this announcement:

1. lodged a complaint with the Cyberspace Administration of the People’s Republic of China 中華人民共和國國家互聯網信息辦公室 against the disruption of the securities trading markets by Flaming by fabricating or disseminating false allegations in the Report causing serious consequences;
2. filed the matter with the competent public security authority of the People’s Republic of China to investigate into such illegal act. The authority officially accepted the case and issued a notice of acceptance in written form (受案回執) on 30 September 2018;
3. engaged legal counsel to prepare a submission and report to the Securities and Futures Commission of Hong Kong on the possible market misconduct by the relevant persons in relation to the matters set out in the Announcement; and
4. instructed legal counsel to assess and take all necessary legal actions (including but not limited to initiating commercial litigation and criminal investigation) against the misconduct of Flaming. The specific legal proceedings may not necessarily be limited to Hong Kong jurisdiction, and the Company may, where necessary, commence legal actions in other relevant jurisdictions.

The Company will update the Shareholders and potential investors as and when appropriate of any further development related to the investigation of the matter.

The Company wishes to emphasize that the business operational and financial conditions of the Company continue to remain normal and healthy. The Company has always and will continue to strive to build on its core competitiveness in order to maximize return for its Shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 1 October 2018

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* For identification purposes only